newsfilter
← Latest News
GlobeNewswire·

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

  • SeaStar Medical Holding Corporation (NASDAQ: ICU) will report third quarter financial results after market close on Thursday, November 13, 2025.
  • The company will host a webcast & conference call to discuss financial results & business progress at 4:30 p.m. ET / 2:30 p.m. MT on November 13, 2025.
  • Pre-registration is required to receive a telephone number & passcode for the conference call.
  • A replay of the webcast will be available after 7:30 p.m. ET.
  • SeaStar Medical is a commercial-stage company focused on treatments for critically ill patients facing organ failure.
  • QUELIMMUNE (SCD-PED) is the company's first commercial product, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients.
  • The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation from the FDA for six therapeutic indications.
  • A pivotal trial for the SCD therapy in adult patients with acute kidney injury requiring continuous renal replacement therapy is currently ongoing.